Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

12/15-lipoxygenase is an interleukin-13 and interferon-gamma counterregulated-mediator of allergic airway inflammation.

Authors: Lindley, AR  Crapster-Pregont, M  Liu, Y  Kuperman, DA 
Citation: Lindley AR, etal., Mediators Inflamm. 2010;2010. pii: 727305. Epub 2010 Sep 29.
Pubmed: (View Article at PubMed) PMID:20953328
DOI: Full-text: DOI:10.1155/2010/727305

Interleukin-13 and interferon-gamma are important effectors of T-helper cells. Interleukin-13 increases expression of the arachidonic acid-metabolizing enzyme, 15-lipoxygenase-1, in a variety of cell types. 15-lipoxygenase-1 is dramatically elevated in the airways of subjects with asthma. Studies in animals indicate that 15-lipoxygenase-1 contributes to the development of allergic airway inflammation but is protective in some other forms of inflammation. We tested the hypothesis that the ability of interleukin-13 and interferon-gamma to counterregulate allergic airway inflammation was potentially mediated by counterregulation of 12/15-lipoxygenase, the mouse ortholog of 15-lipoxygenase-1. The airways of mice were treated with interleukin-13 or interferon-gamma one day prior to each of the four allergen exposures. Interleukin-13 augmented and interferon-gamma inhibited allergic airway inflammation independently of systemic IgE and mucosal IgA responses but in association with counterregulation of 12/15-lipoxygenase. Interleukin-13 and interferon-gamma counterregulate 12/15-lipoxygenase potentially contributing to the effects of these cytokines on allergic airway inflammation.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 4145525
Created: 2010-11-09
Species: All species
Last Modified: 2010-11-09
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.